Shanghai MicroPort Endovascular MedTech Co., Ltd.
Shanghai MicroPort Endovascular MedTech Co., Ltd., commonly referred to as MicroPort, is a leading player in the medical technology industry, headquartered in Shanghai, China. Founded in 2000, the company has established itself as a pioneer in endovascular solutions, focusing on innovative products for vascular interventions. MicroPort operates extensively across Asia, Europe, and the Americas, offering a diverse range of core products, including stent grafts and catheter systems. These products are distinguished by their advanced design and technology, aimed at improving patient outcomes in minimally invasive procedures. With a commitment to research and development, MicroPort has achieved significant milestones, positioning itself as a trusted name in the global market. The company’s dedication to quality and innovation has garnered numerous accolades, solidifying its reputation as a leader in endovascular medical devices.
DitchCarbon Score
How does Shanghai MicroPort Endovascular MedTech Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Shanghai MicroPort Endovascular MedTech Co., Ltd.'s score of 22 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Shanghai MicroPort Endovascular MedTech Co., Ltd.'s reported carbon emissions
In 2023, Shanghai MicroPort Endovascular MedTech Co., Ltd. reported total carbon emissions of approximately 48,747,000 kg CO2e. This figure includes about 3,168,000 kg CO2e from Scope 1 emissions and approximately 45,579,000 kg CO2e from Scope 2 emissions. In comparison, the previous year, 2022, the company recorded total emissions of about 48,310,000 kg CO2e, with Scope 1 emissions at approximately 1,580,000 kg CO2e and Scope 2 emissions at around 46,730,000 kg CO2e. Despite the slight increase in total emissions from 2022 to 2023, there are currently no publicly disclosed reduction targets or climate pledges from Shanghai MicroPort. The company has not reported any Scope 3 emissions, indicating a focus on direct and indirect emissions from its operations and energy use. As of now, there are no emissions data cascaded from a parent or related organization, and all reported figures are directly from Shanghai MicroPort Endovascular MedTech Co., Ltd. The company continues to operate within the global medical technology sector, which is increasingly prioritising sustainability and carbon reduction initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 1,580,000 | 0,000,000 |
| Scope 2 | 46,730,000 | 00,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Shanghai MicroPort Endovascular MedTech Co., Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
